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13-acetate–induced  (DMBA/TPA-induced)  skin  cancer  (33), 
genetic models of liver cancer (12) a carcinogen-induced model 
of colorectal cancer (13), and pancreatic cancer xenografts (14). 
These  preclinical  experiments with TNF-α  antagonists  and 
early-phase clinical trials of TNF-α antagonists in patients with 





















































Disease stabilization in TNFR1 bone marrow chimeras. (A) TNFR1–/– bone marrow, WT bone marrow, and reverse (WT bone marrow in 
TNFR1–/– mice) chimeras were i.p. injected with 107 ID8 cells/mouse. Tumor burden was monitored weekly in situ by bioluminescence. 
TNFR1–/– bone marrow chimeras had significantly lower disease burden, starting 4 weeks after tumor cell injection (P < 0.01). Data are rep-
resented as mean ± SEM of n = 12. Representative data are shown from 2 independent experiments. (B) Total cell counts in the malignant 
ascites at week 8. Cytospins were prepared from ascitic fluid, and cells were differentiated with Wright’s staining. TNFR1–/– bone marrow 
chimeras had a significantly lower neutrophil infiltrate in the peritoneal cavity (P < 0.05, n = 12). Data are represented as mean ± SD of 
n = 12. Representative data are shown from 2 independent experiments. Data for WT (control mice, no chimeras) and reverse chimeras are 
shown in Supplemental Figure 1. (C) FACS analysis of the ascitic leukocyte infiltrate. TNFR1–/– bone marrow chimeras had significantly fewer 
infiltrating Gr-1+ F4/80– neutrophils (P < 0.01, n = 6). Data are represented as percentage of the CD45+ population, including mean of n = 6. 
Representative data are shown from 2 independent experiments (week 8). (D) WT mice were injected with 107 ID8-luc cells i.p.; Gr-1–neu-
tralizing antibody or IgG control antibody were commenced twice weekly i.p. (100 μg/mouse). Data are represented as mean + SEM of n = 6. 
Representative data are shown from 2 independent experiments (week 8).
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Functional CD4 TNFR1 signaling is crucial for tumor progression. 





gene  (37). While TNFR1flcneo mice  reflect TNFR1–/– mice,  the 
Figure 2
Tissue-specific reconstitution of TNFR1. Data are represented as mean ± SEM of n = 6. TNFR1flcneo mice had significantly lowered disease 
burden (P < 0.01) compared with WT mice. (A) TNFR1 gain of function in the monocyte/macrophage lineage has (TNFR1DLysM) no effect on 
tumor growth. (B) TNFR1 gain of function in CD19+ cells (TNFR1ΔCD19) has no effect on tumor growth. (C) Gain of function of TNFR1 in the 
CD4 lineage of TNFR1ΔCD4 mice “rescued” the protective effect of TNFR1 depletion. (D) Western blot for TNFR1 on protein lysates from CD4+ 
cells shows knockin of TNFR1 in CD4+ cells of TNFR1ΔCD4+ mice but not CD19+ or CD11b+ cells. (E) ID8 tumor–bearing TNFR1flcneo mice have 
significantly fewer neutrophils in the malignant ascitic fluid (P < 0.05; compared with WT mice). This effect is reversed in TNFR1ΔCD4 mice 
(P < 0.05; compared with TNFR1flcneo). Data are represented as mean ± SD of n = 6. (F) FACS analysis of the ascitic CD4+ population. TNFR1flcneo 
tumor-bearing mice have significantly fewer ascitic Th17 cells (P < 0.01, n = 6) compared with WT and TNFR1ΔCD4 mice. (G) IL-17 mRNA 
expression in CD4+ cells isolated from ascites of tumor–bearing mice at 8 weeks. (H) Ascitic CD4+ cells were selected and pooled (n = 3) and ex 
vivo stimulated with PMA and ionomycin for 4 hours. CD4+ cells from TNFR1–/– chimeras or TNFR1flcneo mice secreted significantly lower amounts 
of IL-17 (P < 0.01). Data are represented as mean ± SD of n = 6. Representative data are shown from 2 independent experiments.
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respective TNFR1Δ mice gained TNFR1 function in different 
leukocyte populations.





















































Analysis of cytokine expression during tumor progression in tumor-bearing mice at 4, 6, and 8 weeks. Mice were sacrificed and bled for plasma 
collection. (A) IL-6 analysis. (B) IL-17 analysis. Analysis showed no baseline difference (in non–tumor-bearing mice) for any of the analyzed 
cytokines (white bars in the 4-week graph). IL-6 and IL-17 levels are significantly lower in ID8 tumor–bearing mice 6 and 8 weeks after ID8 cell 
injection (P < 0.01, n = 6). Data are represented as mean + SD of n = 6. Representative data are shown from 2 independent experiments.
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Increased IL-17–dependent neutrophil recruitment. (A) Recombinant IL-17 rescued the antitumor effect in TNFR1flcneo mice (P < 0.01). Data are 
represented as mean ± SEM of n = 6. Representative data are shown from 2 independent experiments. The right-hand graph demonstrates the 
curves for only TNFR1cneo mice with or without recombinant IL-17. (B) Total cell counts of the leukocyte infiltrate in the malignant ascites at week 
8 (after i.p. injection). Control (left): significantly lower neutrophils in TNFR1flcneo ID8 tumor–bearing mice compared with WT mice (P < 0.01). 
Treatment with recombinant murine IL-17A (0.5 μg/mouse/week; right): recombinant IL-17A rescued neutrophil infiltration in TNFR1flcneo ID8 
tumor–bearing mice. Data are represented as mean + SD of n = 6. Representative data are shown from 2 independent experiments.
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In vivo treatment with murine anti–TNF-α in a preclinical model of stage 4 ovarian cancer. (A) Neutralizing TNF-α antibody (50 μg/mouse) admin-
istered twice weekly led to disease stabilization in ID8 tumor–bearing mice (P < 0.01). Data are represented as mean ± SEM of n = 10. (B) IL-17 
plasma and ascites levels (8-week time point). Anti–TNF-α–treated mice had significantly lower IL-17 levels (P < 0.01). Data are represented 
as mean ± SD of n = 10. (C) Ascitic leukocyte infiltration. Within the ascitic fluid of anti–TNF-α–treated mice were significantly fewer neutrophils 
(P < 0.05; anti–TNF-α vs. IgG control, anti–TNF-α vs. PBS). Data are represented as mean + SD of n = 10. (D) FACS analysis of the CD4+ 
subpopulation within ID8 tumor–bearing mice. Anti–TNF-α treatment led to a significant reduction in the CD4+IL-17+IFNγ– population compared 
with control IgG- or PBS-treated mice. Data are represented as mean + SD of n = 10. (E) FACS analysis of the Gr-1+ F4/80– population in the 
ascitic fluid. Significant reduction of neutrophils in the anti–TNF-α–treated group. Data are represented as percentage of the CD45+ population 
including mean ± SD of n = 10. (F) Neutralizing IL-17A antibody (100 μg/mouse) administered twice weekly led to neutrophil depletion (insert) 
and disease stabilization in ID8 tumor–bearing mice (P < 0.01). Data are represented as mean ± SEM of n = 10. Representative data are shown 
from 2 independent experiments.
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Patients with advanced malignancies treated with anti–TNF-α in phase I clinical trial. (A) 40 patients with a variety of malignancies were treated 
in a phase I/II clinical trial with infliximab (36). Plasma analysis before and 24 hours after treatment with infliximab demonstrated that anti–TNF-α 
significantly reduced the plasma levels of IL-17 (P < 0.05). Data are represented as mean ± SD of n = 40. (B) Analysis of IL-17 levels in stable 
(SD) versus progressive disease (PD) patients (P < 0.05). In both groups, IL-17 levels dropped significantly 24 hours after anti–TNF-α treatment. 
Data are represented as mean ± SD of n = 40. (C) Cytokine release assay: whole-blood samples were collected from patients in the presence of 
PHA. IL-17 release was significantly lower 24 hours after anti–TNF-α treatment (P < 0.05). Similar results were obtained for D. IL-6 (P < 0.05).
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Ovarian cancer patients with advanced 
disease treated with infliximab in a phase 
I/II clinical trial. Seventeen patients with 
advanced ovarian cancer received i.v. 
anti–TNF-α treatment in this clinical study. 
(A) TNF-α concentrations (P < 0.05) were 
significantly lower at 1 hour (serum) and 
24 hours (ascitic fluid) after infliximab infu-
sion. Data are presented as mean ± SD of 
n = 17. (B) IL-17 protein levels were signifi-
cantly reduced in the ascitic fluid 24 hours 
after infliximab infusion (P < 0.05); however, 
there was no difference in IL-17 plasma lev-
els. Data are represented as mean ± SD 
of n = 15. (C) TNF-α real-time analysis of 
ascitic cell total RNA. TNF-α gene expres-
sion was significantly reduced 24 hours after 
anti–TNF-α treatment (P < 0.01). Data are 
represented as mean ± SD of n = 15. (D) 
IL-17 real-time analysis of ascitic cell total 
RNA. IL-17 gene expression was signifi-
cantly reduced 24 hours after anti–TNF-α 
treatment (P < 0.01). Data are represented 
as mean ± SD of n = 15. (E and F) Cytokine 
release assay: whole-blood samples were 
collected from patients in the presence of 
PHA. Cytokine release was measured by 
ELISA. IL-17 release was significantly lower 
24 hours after anti–TNF-α treatment (E; 
P < 0.05); similar results were obtained for 
IL-6 (F; P < 0.05). (G) CD4+CD25– cells were 
purified by FACS sorting following MACS 
bead isolation from ascites samples before 
treatment and 24 hours after infliximab infu-
sion. Control naive CD4+CD25– T cells were 
selected from peripheral blood of healthy 
blood donors. Data are represented as mean 
+ SD of n = 10; *P < 0.01.
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Gene array analysis. 285 samples of ovarian cancer data sets were ranked from low to high levels of gene expression in the TNF signaling path-
way. The 50 samples with the highest expression of genes in this individual pathway and 50 samples with the lowest expression of these genes 
were analyzed. Network objects (or genes) that make up the pathway “cytokine production in Th17 cells” are represented as a heat map.
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Recombinant mouse  IL-17A  (rmIL-17; R&D Systems) was  dilut-
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pathway,  a  possible  mechanism  for  asbestos-
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